nature portfolio

Corresponding author(s):	Zhongheng Zhang
Last updated by author(s):	Jun 5, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

\sim			
Λt	·at	ist	ICC

n/a	Confirmed
	\square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
\boxtimes	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\times	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\times	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection Data

Data were collected from original articles; and the R package (version 4.01) was used for analysis.

Data analysis

Provide a description of all commercial, open source and custom code used to analyse the data in this study, specifying the version used OR state that no software was used.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our <u>policy</u>

All data were available in the original publications.

Human rese	arch parti	cipants	
Policy information	about <u>studies i</u>	nvolving human research participants and Sex and Gender in Research.	
Reporting on sex	and gender	This information is not collected in individual patient level.	
Population chara	acteristics	see above	
Recruitment		No participants were recruited for the current study.	
Ethics oversight		This is a systematic review does not require ethical approval.	
Note that full informa	ation on the appr	oval of the study protocol must also be provided in the manuscript.	
Field-spe	ecific re	porting	
Please select the o	ne below that i	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.	
X Life sciences		ehavioural & social sciences	
For a reference copy of t	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>	
Life scier	nces sti	udy design	
All studies must dis	sclose on these	points even when the disclosure is negative.	
Sample size	his is a systematic review does not require sample size calculation.		
Data exclusions	susceptibility to	ot compare clinical outcomes were excluded; reviews, animal studies, non-relevant interventions (such as antimicrobial esting), irrelevant subjects (such as delirium management and prediction of AKI), pediatric patients (age < 16 years old), and ere excluded from the review.	
Replication	NA		
Randomization	no randomization was performed		
Blinding	NA		
We require informati	ion from authors	Decific materials, systems and methods about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.	
Materials & ex	perimental s	ystems Methods	
n/a Involved in th	ne study	n/a Involved in the study	
Antibodies		ChIP-seq	
Eukaryotic cell lines Flow cytometry			
Palaeontology and archaeology MRI-based neuroimaging			
Animals and other organisms Clinical data			
Dual use research of concern			

Clinical data

Policy information about <u>clinical studies</u>

All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration PROSPERO: CRD42022299219

Study protocol	PROSPERO: CRD42022299219
Data collection	na
Outcomes	Mortality; length of stay in ICU and hospital